Although CD30 is an effective target for lymphoma therapy, reports of CAR-T cell therapy targeting PTCL based on CD30 mAb remain limited [28]. This evidence concerns the gene TNFRSF8 and mature T-cell and NK-cell non-Hodgkin lymphoma.